Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,444 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07600476RecruitingPhase 1
Safety Study of KUP-101A in Advanced Solid Tumors
This is an early-stage study testing a new drug called KUP-101A in patients with advanced solid cancers (like lung, colon, or breast cancer) that haven't responded to standard treatments. The drug works by activating the immune system to fight cancer.
Munich, BavariaAges 18 years+ - NCT07602855RecruitingPhase 1/Phase 2
Combination treatment for advanced lung cancer
This study tests a new combination of two investigational drugs for people with advanced solid tumors, especially lung cancers. The goal is to see if the combination can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07563829RecruitingPhase 1
NPX372 immunotherapy for advanced solid tumors
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
La Jolla, CaliforniaAges 19 years+ - NCT06740240RecruitingEarly Phase 1
68Ga-FAPI-Biotin PET/CT scan for cancer imaging
This trial tests a new PET/CT scan that uses a special tracer (68Ga-FAPI-Biotin) to help detect and see various solid tumors. It may provide more detailed images to guide treatment decisions.
FuzhouAges 18–90 - NCT06739395RecruitingPhase 2
Precision cancer trial for patients out of standard options
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05882292RecruitingPhase 2
Study of a c-MET drug for advanced solid tumors
This Phase 2 trial tests whether a c-MET inhibitor can slow or shrink advanced solid tumors that have specific c-MET genetic changes. You may be eligible if your cancer has progressed after standard treatment and you meet safety and heart/health requirements.
Seoul, SeoulAges 19 years+ - NCT07533708RecruitingPhase 1
Testing HLX3902 for advanced cancers, especially prostate cancer
This study tests a new drug called HLX3902 in patients with advanced cancers that have stopped responding to standard treatments. The drug targets a protein called STEAP1 and may help slow or stop cancer growth.
NanchangAges 18 years+ - NCT07525141RecruitingPhase 1
Testing JNJ-1761981 for advanced solid tumors
This early-stage trial tests a new drug called JNJ-1761981 in people with solid tumors (cancers that form in organs or tissues, excluding brain tumors) that have spread or returned after standard treatment. The study aims to find the right dose and see how well the drug works.
Jacksonville, FloridaAges 18 years+ - NCT07523529RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Solid Tumors
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Shenzhen, GuangdongAges 18–75 - NCT07505771RecruitingPhase 1
A study of 177Lu-IM-3050 for advanced solid tumors
This trial tests a new treatment called 177Lu-IM-3050 for people with advanced solid tumors that have not responded to or stopped working with standard treatments. The treatment targets a protein called FAP found on some cancer cells and may help shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+ - NCT07498725RecruitingPhase 1/Phase 2
Study of LRK-4189 for solid tumors that have spread or can't be removed
This trial tests a new drug called LRK-4189, alone or with other treatments, for people with advanced solid tumors that have worsened despite prior therapy. The goal is to see if it is safe, tolerable, and helpful against the cancer.
NiceAges 18 years+ - NCT07486713RecruitingPhase 4
Olutasidenib drug interaction study for IDH1 mutation cancers
This trial tests how olutasidenib interacts with other drugs in people with cancers that have an IDH1 mutation, like certain leukemias or brain tumors. Participation may help determine the best way to take this treatment safely.
Orange, CaliforniaAges 18 years+ - NCT06436157Recruiting
Genetic testing support through a nurse-led program
This study tests whether a special program led by oncology nurses can help more people with solid tumor cancers get genetic testing. If you are starting a new treatment and have not had genetic testing before, this program may help you learn about your cancer risks and treatment options.
Chico, CaliforniaAges 18 years+ - NCT07439120RecruitingEarly Phase 1
Testing a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
ShanghaiAges 18 years+ - NCT07378436RecruitingEarly Phase 1
Testing a new drug for cancer-related belly fluid
This early-phase trial tests an experimental drug called GK02 for people with advanced cancer who have fluid buildup in the belly (malignant ascites). The drug is given directly into the belly to try to reduce the fluid and control symptoms.
BeijingAges 18–75 - NCT05098847RecruitingPhase 2
Freezing liver tumors plus anti-cancer drugs for spread cancer
This trial tests whether freezing (cryoablation) liver metastases works better when combined with immunotherapy (sintilimab) and a targeted pill (lenvatinib). It’s for people whose cancer has spread to the liver and has not responded to earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07247110RecruitingPhase 1
Study of MK-4716 for people with certain solid tumors
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
New Brunswick, New JerseyAges 18 years+ - NCT06493552RecruitingPhase 2/Phase 3
Testing sEphB4-HSA in EphrinB2-high bladder cancer
This trial tests a new drug called sEphB4-HSA for people with a specific type of bladder cancer (urothelial carcinoma) that has high levels of a protein called EphrinB2. The study aims to see if this drug can shrink tumors or prevent them from growing, and it compares it to standard treatments like chemotherapy or immunotherapy.
Santa Monica, CaliforniaAges 18 years+ - NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Newport Beach, CaliforniaAges 18 years+ - NCT07209111RecruitingPhase 2
Testing Calderasib for advanced solid tumors with KRAS G12C mutation
This trial tests a new drug, Calderasib (MK-1084), for people with advanced solid tumors that have a specific KRAS G12C mutation and aren't getting better with standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Baltimore, MarylandAges 18 years+ - NCT07187908RecruitingPhase 2
Study of Efbemalenograstim Alfa to prevent low white blood cell counts in cancer patients
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
Zhengzhou, HenanAges 18–75 - NCT07174453RecruitingPhase 3
Comparing side effects of different doses of immunotherapy
This study compares standard dosing schedules of pembrolizumab or nivolumab (two immunotherapy drugs) to see which one causes fewer immune-related side effects. It is for people with solid tumors who are already eligible to receive one of these drugs as part of their standard care.
Westwood, KansasAges 18 years+ - NCT07172919RecruitingPhase 2
Continued treatment with sotorasib for KRAS G12C cancer
This study is for people who are already taking the targeted therapy sotorasib (with or without another drug called panitumumab) in an Amgen clinical trial and are still doing well. It lets you keep receiving the same treatment after your original study ends, so you don't have to stop a medicine that is working for you.
Fort Myers, FloridaAges 18 years+ - NCT06971523RecruitingPhase 1/Phase 2
Study of CTS3497 for cancers missing a specific protein
This trial tests a new drug called CTS3497 in people whose tumors lack a protein called MTAP. The drug aims to stop cancer cells from growing by targeting a weakness caused by this missing protein.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,444 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.